Skip to main content
Clinical Trials/NL-OMON52983
NL-OMON52983
Completed
Phase 4

A randomised, open-label clinical trial assessing the efficacy and safety of mycophenolate mofetil versus azathioprine for induction of remission in treatment naive autoimmune hepatitis - CAMARO

eids Universitair Medisch Centrum0 sites66 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Autoimmune hepatitis
Sponsor
eids Universitair Medisch Centrum
Enrollment
66
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Trial is onging in other countries

Registry
who.int
Start Date
TBD
End Date
June 1, 2023
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Probable or definite diagnosis of autoimmune hepatitis according to the
  • International Autoimmune Hepatitis Study Group criteria (table 2\) 9:
  • Definite autoimmune hepatitis: \>\= 7
  • Probable autoimmune hepatitis \>\= 6
  • 2\. First presentation of AIH requiring treatment according to the current EASL
  • 3\. Age \>\= 18 years
  • 4\. Must provide informed consent and agree to comply with the trial protocol

Exclusion Criteria

  • 1\. Overlap syndrome with PSC or PBC (Paris criteria 29, strong positive AMA,
  • past liver biopsy or cholangiographic findings compatible with PBC or PSC).2\.
  • Presence of clinical significant hepatic decompensation including:• History of
  • liver transplantation, current active placement on a liver transplant waiting
  • Portal hypertension with complications including: poorly controlled or
  • diuretic resistant ascites, history of variceal bleeding or related therapeutic
  • interventions (e.g. variceal banding, transjugular intrahepatic portosystemic
  • shunts) or hepatic encephalopathy.
  • Cirrhosis with complications, including history or presence of: spontaneous
  • bacterial peritonitis, hepatocellular carcinoma, hepatorenal syndrome

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
A randomised, open-label clinical trial assessing the efficacy of octreotide to decrease iron infusion and blood transfusion requirements in patients with refractory anaemia due to gastrointestinal bleeding from angiodysplasias.angiodysplasiavascular malformation10017959
NL-OMON44271Maag-, darm- en leverziekten62
Completed
Phase 2
A randomised, controlled, double-blind trial to investigate the effects of a new infant formula on growth, tolerance and safety in healthy term infants.effect op de groei van zuigelingeneffects on growth
NL-OMON39783utricia Research - Centre for Specialised Nutrition121
Completed
Phase 4
Prospective, randomized, open label trial of six vs. twelve months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction.DAPT treatment after PCIDual-antiplatelettherapy after stent implantation10011082
NL-OMON39800Maasstadziekenhuis580
Completed
Phase 2
A randomized, open-label, parallel-group, multi-center study of adding edoxaban or clopidogrel to aspirin to maintain patency in subjects with peripheral arterial disease following femoropopliteal endovascular intervention-edoxaban in peripheral arterial disease (ePAD)narrowing of the peripheral arteries (mostly in the legs)periferal arterial disease10003216
NL-OMON40071Daiichi Sankyo Development Ltd14
Completed
Phase 2
A Randomised, Double-Blind, Placebo-Controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary AlveoLAr Proteinosis Patients
NL-OMON46238Savara ApS9